September 7, 2005 |
Barr Pharmaceuticals Inc. and Teva Pharmaceutical Industries Ltd. said they would cooperate in launching generic versions of Sanofi-Aventis' Allegra allergy drug. Barr of Pomona, N.Y., received final approval last week for the generic drug from the Food and Drug Administration. Allegra sales were worth $1.4 billion for the 12 months ended in June, according to research firm IMS Health.
August 24, 2005 |
Generic-drug makers including Ivax Corp. and Teva Pharmaceutical Industries Ltd. aren't infringing patents on Pfizer Inc.'s epilepsy drug Neurontin by selling low-cost versions, a federal judge ruled. U.S. District Judge John Lifland in Newark, N.J., said the generic version of gabapentin, the key ingredient in Neurontin, didn't infringe. Pfizer will appeal, spokesman Paul Fitzhenry said. Teva, Ivax and Alpharma Inc.
June 7, 2005 |
Pfizer Inc. and other drug companies have the right to sell unbranded versions of their own drugs even if they undercut sales of generic competitors, a U.S. appeals court has ruled. Teva Pharmaceutical Industries Ltd., the world's biggest generic-drug maker, sued in August to stop Pfizer from selling a lower-cost version of the epilepsy drug Neurontin. The U.S. Court of Appeals for the District of Columbia Circuit, in a ruling Friday, said the law didn't prohibit such "authorized generics."
April 15, 2005 |
A federal judge Thursday turned away the claims of generic drug manufacturers and ruled valid a patent for Eli Lilly & Co.'s drug Zyprexa. U.S. District Judge Richard Young in Indianapolis ruled in favor of Lilly on all of the matters in dispute in the case, Lilly said. However, appeals are likely. The ruling is a huge relief to Lilly, Chief Executive Sidney Taurel said.
January 22, 2005 |
Allergan Inc., the maker of Botox, said Friday that a federal court dismissed the company's lawsuit seeking to win reclassification of its Restasis treatment for dry eyes, which would have prevented the sale of a generic version for three years. The U.S. District Court in Washington agreed with the Food and Drug Administration's classification of Restasis as an antibiotic, according to court papers.
August 31, 2004 |
Mylan Laboratories Inc. said it had withdrawn a lawsuit against the Food and Drug Administration concerning deals involving the makers of brand-name and generic drugs, but said it might refile the suit with additional complaints. Mylan sued the FDA in early July to protest the agency's support for a practice by some pharmaceutical companies to authorize a generic drug company to sell a version of a particular brand-name drug.
July 13, 2004 |
A potential trade agreement between Thailand and the United States could derail this country's production of inexpensive AIDS drugs and imperil the future of an anti-HIV program that is widely considered a model for countries throughout Asia, the group Doctors Without Borders said Monday. "If the Thais sign such an agreement, they will have to close down their generic drug production," Paul Cawthorne of the Belgium-based group told a news conference.
February 14, 2004 |
Allergan Inc., the maker of Botox anti-wrinkle treatments, said the Federal Trade Commission had closed its investigation into whether the company hindered generic drug makers from making copies of its Acular eye drug. Irvine-based Allergan said the decision followed a U.S. District Court ruling in December that concluded the patent covering Acular was valid and enforceable, the company said.
August 20, 2003 |
Novartis became the third company to launch a generic version of AstraZeneca's heartburn and ulcer pill Prilosec in the United States, intensifying a multibillion-dollar market fight. Novartis already markets a generic version of Prilosec in Europe through its Sandoz division. The product was developed by Novartis' Slovenian unit, Lek. Germany's Schwarz Pharma successfully challenged AstraZeneca's exclusivity last year, and this month Mylan Laboratories Inc.
June 20, 2003 |
The Senate on Thursday approved a long-stalled measure to make it easier to get cheaper generic prescription drugs to market, adding an important cost-control provision to legislation that would expand Medicare to cover pharmaceuticals. The generic-drug measure, a compromise offered as an amendment to the Medicare bill, would close patent-law loopholes that allow brand-name drug manufacturers to protect themselves from competition by delaying the sale of generic equivalents.